https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17127 Sat 24 Mar 2018 08:02:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20776 Sat 24 Mar 2018 08:00:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21556 Sat 24 Mar 2018 07:49:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27241 Sat 24 Mar 2018 07:29:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34286 Fri 22 Apr 2022 10:19:33 AEST ]]>